736 , Shakti Khund III , New Delhi
+1778-732-2562

Global Immunotherapy Drugs Market By Type(Monoclonal Antibodies, Checkpoint Inhibitor, others), By Therapeutic Area (Cancer, Infectious Disease, Others), By End User (Hospitals, Clinics, Others), By Region–Forecast & Opportunities to 2026

Report Description

The immunotherapy drugs market valued USD 146.1 billon in year 2019. The immunotherapy drugs market is estimated to foresee growth at a CAGR of 9.1% during the period of 2020-2026.

COVID-19 has impacted all the businesses across the globe. World Health Organization has declared Corona virus as a global pandemic. The COVID19 has disrupted the Immunotherapy market. People across the world are afraid entering the hospitals due to corona virus. Hence due to COVID-19 the immunotherapy market is estimated to foresee decline in its initials phase of forecast period but it can witness growth in latter phase of forecast period.

Definition:

Immunotherapy drugs are majorly used to enhance immune system of the body. Immunotherapy drugs are mostly used in cancer treatment. Immunotherapy drugs act by simulating our body’s immune system. They generated immune response in our body with the help of production of antibodies. Our body produced antibodies against antigen which kills the tumor or cancerous cells.

Market Dynamics (Drivers/Opportunities):

The rising prevalence of chronic diseases and increasing demand for biosimilars and monoclonal antibodies are the factors driving immunotherapy market towards growth. The adoption of immunotherapy drugs largely over conventional treatments nowadays is another driving factor for immunotherapy drugs market.

Government is spending a lot in developing healthcare infrastructure to facilitate various healthcare services involving immunotherapy and etc. Along with government many private players are also investing for the development of healthcare infrastructure. This is also driving factor for immunotherapy market.

The number of cases of chronic diseases is increasing worldwide. In order to treat such chronic diseases hospitals and clinics are largely adopting immunotherapy drugs over conventional methods of treatment as immunotherapy have less side-effects which is driving the market towards growth.

Market Insights, by Type

On the basis of type the immunotherapy drug market is segmented into monoclonal antibodies, interferon & interleukins and checkpoint inhibitors. The monoclonal segment accounted for maximum market share in year 2019. The major driving factors are fewer side effects and specificity. Focus on personalized medicines is increasing and rise in cases of chronic diseases are driving the market.

Market Insights, by Therapeutic Area

On the basis of therapeutic area the immunotherapy drug market is segmented into cancer, Infectious diseases, auto immune & inflammatory disease and others. Cancer segment had registered maximum market share in 2019.

Cancer segment is expected to grow at a higher CAGR during the forecast period. The rising number cancer cases require the major attention. In 2015 world health organization declared cancer as second largest cause of death worldwide. Rising research activity and government attention are the major market drivers.

Market Insights, by End-Users

On the basis of end-user the immunotherapy drug market is segmented into hospitals, clinics and treatments. Hospitals accounted for maximum market share in 2019. Hospitals are spending at a large scale in immunotherapy.

Hospitals segment in immunotherapy drugs market is expected to account for higher market share by value. Hospital segment is projected to grow at h CAGR of XX% during the period of 2020-2026. The number chronic disease case are rising worldwide and only hospitals are providing advanced treatment for such diseases, owing to drive the market to witness highest growth.

Regional Insights

Based on regions, North America was accounted for maximum market share in year 2019. It is expected to maintain its dominance during the forecast period and projected to register growth at highest CAGR during the forecast period. There are many favorable government initiatives support this market segment. The private organizations are investing more in R&D department to provide technologically advanced products. The number chronic disease cases are more in this area. In 2016, 1.75 million new cancer cases were likely to be detected in U.S.

After North America, Asia-Pacific region is expected to register growth at higher rate. It is projected to grow at a CAGR of XX% during the period of 2020-2026. This region comprises of large population leading to larger number of chronic disease cases and the key companies are investing much higher in this segment. Both this factors are driving the immunotherapy drugs market in this region.

Key Companies & Market Share Insights

The key market players in immunotherapy drugs market are Pfizer Inc., Novartis AG, F. HoffmannLa Roche Ltd., Johnson & Johnson, Sanofi, Glaxo Smith Kline Plc, Amgen Inc., Merk& Co., Abb Vie Inc., AstraZeneca, Immatics, Boehringer Ingelheim, Biotechnologies, BioNTech SE, Gnmab,, NBE Therapeutics, Teva Phamaceuticals, Bayer, Gilead Sciences and Bristol-Myers Squibb.

Segments Covered in the Report

This report forecasts The Immunotherapy Drug Market, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2026. For the purpose of this study, Our Company has segmented the global immunotherapy drug market report on the basis of type, therapeutic area, and end-user.

Immunotherapy Drugs Market Size & Forecast (2017-2026)

  1. Research Framework
    • Market Definition and Product Overview
    • Market Segmentation
  2. Research Methodology
    • Qualitative Research
      • Primary & Secondary Sources
    • Quantitative Research
      • Primary & Secondary Sources
    • Breakdown of Primary Research Respondents, By Region
      • Secondary Research
      • Primary Research
    • Breakdown of Primary Research Respondents, By Industry Participants
      • Market Size Estimation
      • Assumption for the Study
      • Market Breakdown & Data Triangulation
  3. Executive Summary
    • Market Snapshot
  4. Industry Insights
    • Industry ecosystem analysis
      • ValueChain Analysis
    • Industry impact and forces
      • Growth Drivers
      • Challenges &Restraints
      • Opportunities
    • Disruptive Technological Analysis
    • Regulatory framework
      • North America
      • Europe
      • Asia Pacific
      • Middle East & Africa
      • South America
    • Growth potential analysis, 2019
    • Porter’s Five forces analysis
    • Pricing Analysis
      • North America
      • Europe
      • Asia Pacific
      • Middle East & Africa
      • South America
  1. COVID – Impact Analysis
    • North America
    • Europe
    • Asia Pacific
    • Middle East & Africa
    • South America
  2. Immunotherapy Drugs Market, By Type Market Size & Forecast To 2026

(USD Million 2017,2018, 2019, 2020, 2021-e-2026-p)

  • Introduction
  • Monoclonal Antibodies
  • Interferon & Interleukins
  • Checkpoint Inhibitors
  1. Immunotherapy Drugs Market, By Therapeutic Area Market Size & Forecast To 2026

(USD Million 2017,2018, 2019, 2020, 2021-e-2026-p)

  • Introduction
  • Cancer
  • Infectious Diseases
  • Autoimmune & Inflammatory Disease
  • Others Therapeutic Diseases
  1. Immunotherapy Drugs Market, By End User, Market Size & Forecast To 2026

(USD Million 2017,2018, 2019, 2020, 2021-e-2026-p)

  • Introduction
  • Hospitals
  • Clinics
  • Treatment
  • Others
  1. Immunotherapy Drugs Market, By Region, Market Size & Forecast To 2026

(USD Million 2017,2018, 2019, 2020, 2021-e-2026-p)

  • Introduction
  • North America Market Size & Forecast To 2026
    • Market Overview
    • COVID-19 Impact
    • By Type
    • By Therapeutic Area
    • By End-User
    • By Country
      • USA
        • By End-User
      • Canada
      • Mexico
    • South America Market Size & Forecast To 2026
      • Market Overview
      • COVID-19 Impact
      • By Type
      • By Therapeutic Area
      • By End-User
      • By Country
        • Brazil
          • By End-User
        • Argentina
        • Chile
        • Rest of South America
      • Europe Market Size & Forecast To 2026
        • Market Overview
        • COVID-19 Impact
        • By Type
        • By Therapeutic Area
        • By End-User
        • By Country
          • UK
            • By End-User
          • Germany
          • France
          • Italy
          • Rest of Europe
        • APAC Market Size & Forecast To 2026
          • Market Overview
          • COVID-19 Impact
          • By Type
          • By Therapeutic Area
          • By End-User
          • By Country
            • China
              • By End-User
            • India
            • Japan
            • South Korea
            • Australia
            • Rest of APAC
          • Middle East & Africa Market Size & Forecast To 2026
            • Market Overview
            • COVID-19 Impact
            • By Type
            • By Therapeutic Area
            • By End-User
            • By Country
              • Saudi Arabia
                • By End-User
              • UAE
              • Qatar
              • Kuwait
              • South Africa
              • Rest of Middle East & Africa
  1. Competitive Landscaping
    • Competitive Benchmarking
      • Market Share Analysis, 2019
      • Global Presence and Growth Strategies
        • Mergers & Acquisitions
        • New Product Launches
        • Investments Trends
        • R&D Initiatives
  1. Company Profile
    • Bristol-Myers Squibb
      • Company Overview
      • Financial Overview
      • Product Portfolio
      • Recent Developments
      • SWOT Analysis
      • Strategic Outlook
    • Pfizer Inc.
    • Novartis AG
    • HoffmannLa Roche Ltd.,
    • Johnson & Johnson,
    • Sanofi
    • Glaxo Smith Kline Plc
    • Amgen Inc.
    • Merk& Co.
    • Abb Vie Inc.
    • AstraZeneca
    • Immatics
    • Boehringer Ingelheim
    • Biotechnologies
    • BioNTech SE
    • Gnmab
    • NBE Therapeutics
    • Teva Phamaceuticals,
    • Bayer
    • Gilead Sciences
  2. Appendix
    • Interrelated Market

 

 

Research Methodology

1.1     Research Methodology

The process of market research at PAN Market Consulting is very intuitive being iterative in nature and usually follows the path where Information gathered from secondary research is used to build data models, which are than validated from primary participants. Then same cycle repeats where, according to inputs from primary participants, additional secondary research is done, and new information type is again incorporated into data model. The process continues till desired level of information is not generated.

To calculate the market size, the report considers the revenue generated from the sales of the product/services. The revenue generated from the sales of product/services has been calculated through primary and secondary research. The report also analyses the key players operating in the market at the global level which are identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes product segmentation determined using secondary sources and verified through primary sources.

1.2     Secondary Research

The secondary research source that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • Internal and external proprietary databases, relevant patent and regulatory databases
  • National government documents, statistical databases and market reports
  • News articles, press releases and web-casts specific to the companies operating in the market

The source for secondary research includes but is not limited to Factiva, Hoovers and Statista

SecondaryResearch

1.3     Primary Research

We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following end users:

  • It provides first-hand information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
  • Helps in validating and strengthening the secondary research findings
  • Further develops the analysis team’s expertise and market understanding
  • Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/ product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
  • Key opinion leaders specializing in different areas corresponding to different industry end users

1.4     Models

Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data products to produce estimates:

  • Demographic data: Population split by segment
  • Macro-economic indicators: GDP, etc.
  • Industry indicators: Expenditure, product stage & infrastructure, sector growth and facilities.

Data is then cross checked by the expert panel.

1.4.1 Company Share Analysis Model

Company share analysis is used to derive the size of global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps:

ResearchMethodology1

1.4.2 Revenue Based Modeling

Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach whereas it acts as starting point for top-down approach.

ResearchMethodology2

Please share your details to receive a sample copy of the report

Single User : $3750
Multi User : $6100
Buy Now

 

Why Choose Us

  • 24*7 Post Sales Support
  • Speak to Analyst for Presentations
  • 15% Free Customization
  • Global, Regional & Country level reports
  • Special Discounts for Startups & Educational Institutions

Questions ?

  • What is 15% Free Customization?
  • What is Report Subscription?
  • What is the Delivery Time of the Report?

What You Get

Data Excel Sheets

Report in PDF

Report Subscription

Analyst Support

What's Included

Market Intelligence

Competitive Intelligence

Opportunities and Challenges

Strategic Recommendations